Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 1
2012 1
2013 1
2015 1
2016 2
2017 3
2018 3
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.
Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe SW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ. Li J, et al. Among authors: Rech AJ. Immunity. 2018 Jul 17;49(1):178-193.e7. doi: 10.1016/j.immuni.2018.06.006. Epub 2018 Jun 26. Immunity. 2018. PMID: 29958801 Free PMC article.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Twyman-Saint Victor C, et al. Among authors: Rech AJ. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9. Nature. 2015. PMID: 25754329 Free PMC article.
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Dorfman LM, Lunceford N, Barrett A, Mitra N, Morrissette JJD, Feldman M, Nayak A, Domchek SM, Vonderheide RH, Nathanson KL. Kraya AA, et al. Among authors: Rech AJ. Clin Cancer Res. 2019 Jul 15;25(14):4363-4374. doi: 10.1158/1078-0432.CCR-18-0468. Epub 2019 Mar 26. Clin Cancer Res. 2019. PMID: 30914433
T-Cell Transfer Therapy Targeting Mutant KRAS.
Rech AJ, Vonderheide RH. Rech AJ, et al. N Engl J Med. 2017 Feb 16;376(7):e11. doi: 10.1056/NEJMc1616637. N Engl J Med. 2017. PMID: 28207208 No abstract available.
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer.
Rech AJ, Balli D, Mantero A, Ishwaran H, Nathanson KL, Stanger BZ, Vonderheide RH. Rech AJ, et al. Cancer Immunol Res. 2018 Mar;6(3):276-287. doi: 10.1158/2326-6066.CIR-17-0559. Epub 2018 Jan 16. Cancer Immunol Res. 2018. PMID: 29339376 Free PMC article.
Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency.
Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, Mueller C, Flotte TR, Wilson JM. Calcedo R, et al. Among authors: Rech AJ. Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1655-1659. doi: 10.1073/pnas.1617726114. Epub 2017 Jan 30. Proc Natl Acad Sci U S A. 2017. PMID: 28137880 Free PMC article. Clinical Trial.
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.
Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, Bajor DL, Byrne KT, Stanger BZ, Riley JL, Markosyan N, Winograd R, Vonderheide RH. Evans RA, et al. Among authors: Rech AJ. Version 2. JCI Insight. 2016 Sep 8;1(14):e88328. doi: 10.1172/jci.insight.88328. JCI Insight. 2016. PMID: 27642636 Free PMC article.
Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).
Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, Quinones L, Sela Y, Yamazoe T, Gordon N, Tobias JW, Byrne KT, Rech AJ, FitzGerald GA, Stanger BZ, Vonderheide RH. Markosyan N, et al. Among authors: Rech AJ. J Clin Invest. 2019 Jun 4;129(9):3594-3609. doi: 10.1172/JCI127755. J Clin Invest. 2019. PMID: 31162144 Free PMC article.
16 results
Jump to page
Feedback